Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
TSC2 S1365A mutation potently regulates CD8+ T cell function and differentiation and improves adoptive cellular cancer therapy
Chirag H. Patel, Yi Dong, Navid Koleini, Xiaoxu Wang, Brittany L. Dunkerly-Eyring, Jiayu Wen, Mark J. Ranek, Laura M. Bartle, Daniel B. Henderson, Jason Sagert, David A. Kass, Jonathan D. Powell
Chirag H. Patel, Yi Dong, Navid Koleini, Xiaoxu Wang, Brittany L. Dunkerly-Eyring, Jiayu Wen, Mark J. Ranek, Laura M. Bartle, Daniel B. Henderson, Jason Sagert, David A. Kass, Jonathan D. Powell
View: Text | PDF
Research Article Cell biology Immunology

TSC2 S1365A mutation potently regulates CD8+ T cell function and differentiation and improves adoptive cellular cancer therapy

  • Text
  • PDF
Abstract

MTORC1 integrates signaling from the immune microenvironment to regulate T cell activation, differentiation, and function. TSC2 in the tuberous sclerosis complex tightly regulates mTORC1 activation. CD8+ T cells lacking TSC2 have constitutively enhanced mTORC1 activity and generate robust effector T cells; however, sustained mTORC1 activation prevents generation of long-lived memory CD8+ T cells. Here we show that manipulating TSC2 at Ser1365 potently regulated activated but not basal mTORC1 signaling in CD8+ T cells. Unlike nonstimulated TSC2-KO cells, CD8+ T cells expressing a phosphosilencing mutant TSC2-S1365A (TSC2-SA) retained normal basal mTORC1 activity. PKC and T cell receptor (TCR) stimulation induced TSC2 S1365 phosphorylation, and preventing this with the SA mutation markedly increased mTORC1 activation and T cell effector function. Consequently, SA CD8+ T cells displayed greater effector responses while retaining their capacity to become long-lived memory T cells. SA CD8+ T cells also displayed enhanced effector function under hypoxic and acidic conditions. In murine and human solid-tumor models, SA CD8+ T cells used as adoptive cell therapy displayed greater antitumor immunity than WT CD8+ T cells. These findings reveal an upstream mechanism to regulate mTORC1 activity in T cells. The TSC2-SA mutation enhanced both T cell effector function and long-term persistence/memory formation, supporting an approach to engineer better CAR-T cells for treating cancer.

Authors

Chirag H. Patel, Yi Dong, Navid Koleini, Xiaoxu Wang, Brittany L. Dunkerly-Eyring, Jiayu Wen, Mark J. Ranek, Laura M. Bartle, Daniel B. Henderson, Jason Sagert, David A. Kass, Jonathan D. Powell

×

Figure 1

TSC2 is a central environmental hub that modulates mTORC1 activity and differentiation in T cells.

Options: View larger image (or click on image) Download as PowerPoint
TSC2 is a central environmental hub that modulates mTORC1 activity and d...
(A) Immunoblot analysis of the PI3K/AKT/TSC2/mTORC1 pathway in resting T cells upon dose dependent stimulation of different stimuli for 30 minutes. PMA: phorbol ester, αCD3, IL-2. (B) WT and TSC2–/– CD8+ T cells were stimulated via TCR and Co-Stim with agonists anti-CD3 and anti-CD28 for 1 and 3 hours, and mTORC1 and mTORC2 activity was measured by immunoblot. The 0 hour indicates baseline with no simulation. (C) Flow cytometry proliferation analysis of WT and TSC2–/– CD8+ T cells stimulated and grown in different pH level media conditions. Data are measured on day 3. (D) Different congenic naive WT P14 (gp33+) CD8+ T cells were isolated and CRISPR edited using with CAS9 and a control sgRNA (Ctrl) or 1 of 2 sgRNAs (g1, or g2) targeting TSC2. Ctrl and TSC2 sgRNA–edited CD8+ T cells were mixed at 1:1 ratio and coadoptively transferred into naive WT recipients and infected with LCMV Armstrong for acute (day 8, blood) and memory analysis of donor CD8+ T cells (spleen) via flow cytometry. n = 5/group for guide 1 (g1); n = 6/group for guide 2 (g2); *P < 0.05, **P < 0.01 paired t test. Data are representative of 3 or more independent experiments (A–C), and 2 independent exp (D).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts